CITIUS ONCOLOGY, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
11 COMMERCE DRIVE, CRANFORD, NJ, 07016
Mailing Address
11 COMMERCE DRIVE, CRANFORD, NJ, 07016
Phone
(908) 967-6677
Fiscal Year End
0930
EIN
994362660
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | January 5, 2026 | View on SEC |
| 10-K Annual financial report | December 23, 2025 | View on SEC |
| 8-K Current report of material events | December 23, 2025 | View on SEC |
| 4/A Insider transaction amendment | December 22, 2025 | View on SEC |
Annual Reports
10-K
December 23, 2025
- Citius Oncology, Inc. became a publicly-traded company via a reverse merger in August 2024, remaining majority-owned by Citius Pharmaceuticals, Inc.
- The company's primary objective is to commercialize its product, LYMPHIR™ (denileukin diftitox).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.